# A 6-week Study to Evaluate the Safety and Efficacy of Quillichew ERCT in 4-5 Year Old Children With ADHD.

> **NCT03580005** · PHASE4 · WITHDRAWN · sponsor: **Pfizer**

## Conditions studied

- Attention Deficit Hyperactivity Disorder (ADHD)
- Attention Deficit Hyperactivity Disorder

## Interventions

- **DRUG:** methylphenidate HCl ERCT
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03580005
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-10-31
- **Primary completion:** 2021-10-12
- **Final completion:** 2021-10-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The study was cancelled prior to the enrollment of any participants.
- **Last updated:** 2018-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03580005

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03580005, "A 6-week Study to Evaluate the Safety and Efficacy of Quillichew ERCT in 4-5 Year Old Children With ADHD.". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT03580005. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*